WO2016081773A3 - Traitement anticancéreux combiné avec des inhibiteurs du c-met et des oligonucléotides synthétiques - Google Patents

Traitement anticancéreux combiné avec des inhibiteurs du c-met et des oligonucléotides synthétiques Download PDF

Info

Publication number
WO2016081773A3
WO2016081773A3 PCT/US2015/061687 US2015061687W WO2016081773A3 WO 2016081773 A3 WO2016081773 A3 WO 2016081773A3 US 2015061687 W US2015061687 W US 2015061687W WO 2016081773 A3 WO2016081773 A3 WO 2016081773A3
Authority
WO
WIPO (PCT)
Prior art keywords
met inhibitor
cancer therapy
synthetic oligonucleotides
met inhibitors
combination cancer
Prior art date
Application number
PCT/US2015/061687
Other languages
English (en)
Other versions
WO2016081773A2 (fr
Inventor
Andreas Bader
Jane Zhao
Adriana Guerrero
Original Assignee
Mirna Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirna Therapeutics, Inc. filed Critical Mirna Therapeutics, Inc.
Publication of WO2016081773A2 publication Critical patent/WO2016081773A2/fr
Publication of WO2016081773A3 publication Critical patent/WO2016081773A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)

Abstract

La présente invention concerne des procédés permettant d'inhiber et de prévenir la prolifération de cellules cancéreuses, ainsi que de traiter le cancer chez un individu (par exemple, un cancer du foie, par exemple un carcinome hépatocellulaire), qui peuvent comprendre la fourniture à la fois d'une molécule synthétique de la famille miR-34 et un inhibiteur du c-Met (par exemple, le tivantinib) à un individu ayant besoin d'un tel traitement. La combinaison de la molécule synthétique de miARN et de l'inhibiteur du c-Met peut fournir un effet souhaitable ou supérieur, par exemple un traitement plus efficace qu'un traitement alternatif, ou que la molécule synthétique de miARN seule ou l'inhibiteur du c-Met seul. Dans certains modes de réalisation, les combinaisons fournissent un effet synergique ou supérieur à un effet additif, ou réduisent la toxicité et/ou d'autres effets secondaires.
PCT/US2015/061687 2014-11-19 2015-11-19 Traitement anticancéreux combiné avec des inhibiteurs du c-met et des oligonucléotides synthétiques WO2016081773A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081882P 2014-11-19 2014-11-19
US62/081,882 2014-11-19

Publications (2)

Publication Number Publication Date
WO2016081773A2 WO2016081773A2 (fr) 2016-05-26
WO2016081773A3 true WO2016081773A3 (fr) 2016-07-14

Family

ID=56014683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/061687 WO2016081773A2 (fr) 2014-11-19 2015-11-19 Traitement anticancéreux combiné avec des inhibiteurs du c-met et des oligonucléotides synthétiques

Country Status (2)

Country Link
US (1) US20160151406A1 (fr)
WO (1) WO2016081773A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107532199B (zh) * 2014-07-29 2021-10-22 威马克生物有限公司 与间质上皮转化因子抑制剂有关的感受性预测用新型生物标志物及其用途
WO2017106810A2 (fr) * 2015-12-17 2017-06-22 Novartis Ag Combinaison d'un inhibiteur de c-met avec une molécule d'anticorps dirigée contre pd-1 et ses utilisations
EP3490676A1 (fr) * 2016-07-29 2019-06-05 Eli Lilly and Company Polythérapie à base de méréstinib et d'inhibiteurs anti-pd-l1 ou anti-pd-1 destinée à être utilisée dans le traitement du cancer
CN109982700A (zh) * 2016-11-16 2019-07-05 伊莱利利公司 具有外显子14跳跃突变或外显子14跳跃表型的癌症的治疗
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
WO2023172629A2 (fr) * 2022-03-08 2023-09-14 Brown University Dérivés de maléimide anticancéreux destinés à être utilisés avec un blocage de point de contrôle immunitaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140024548A1 (en) * 2010-12-23 2014-01-23 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506791A (ja) * 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140024548A1 (en) * 2010-12-23 2014-01-23 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLADT, F ET AL.: "The e-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.", CANCERS (BASEL)., vol. 6, no. 3, 19 August 2014 (2014-08-19), pages 1736 - 1752 *

Also Published As

Publication number Publication date
US20160151406A1 (en) 2016-06-02
WO2016081773A2 (fr) 2016-05-26

Similar Documents

Publication Publication Date Title
EP4026835A3 (fr) Inhibiteurs de pd-1/pd-l1
WO2016081773A3 (fr) Traitement anticancéreux combiné avec des inhibiteurs du c-met et des oligonucléotides synthétiques
WO2015023976A3 (fr) Inhibiteurs sélectifs de la grp94 et leurs utilisations
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
WO2014113429A3 (fr) Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux
WO2014164704A3 (fr) Composés et compositions utilisables en vue du traitement du cancer
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
BR112015011830A2 (pt) compostos e seus métodos de utilização
WO2015073587A3 (fr) Complexes membrane synthétique- récepteur
WO2014190163A3 (fr) Polythérapie pour mds
CA2900335C (fr) Analogues synthetiques d'epipolythiodioxopiperazines et leurs utilisations
WO2015095819A3 (fr) Traitement du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la raf
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
CA2908742C (fr) Polytherapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
WO2016160621A3 (fr) Cellules nk-92 utilisées dans une polythérapie en association avec des médicaments anticancéreux
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2016008042A (es) Derivados de imidazopirazinona.
ZA201901367B (en) Inhibition of olig2 activity
WO2015181624A3 (fr) Dérivés de nucléosides pour le traitement du cancer
WO2015089402A8 (fr) Procédés et compositions associés à des inhibiteurs de hsp90 et au cancer du sein
WO2017019721A3 (fr) Thérapies de combinaison pour la modulation d'enzymes de modification de méthyle d'histone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15861735

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15861735

Country of ref document: EP

Kind code of ref document: A2